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Background: The most common form of facioscapulohumeral muscular dystrophy (FSHD) is caused by a genetic
contraction of the polymorphic D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q.
In some studies, genes centromeric to the D4Z4 repeat array have been reported to be over-expressed in FSHD,
including FRG1 and FRG2, presumably due to decreased long-distance repression by the shorter array through
a mechanism similar to position-effect variegation. Differential regulation of FRG1 in FSHD has never been
unequivocally proven, however, FRG2 has been reproducibly shown to be induced in primary FSHD-derived
muscle cells when differentiated in vitro. The molecular function of FRG2 and a possible contribution to FSHD
pathology remain unclear. Recent evidence has identified the mis-expression of DUX4, located within the D4Z4
repeat unit, in skeletal muscle as the cause of FSHD. DUX4 is a double homeobox transcription factor that has
been shown to be toxic when expressed in muscle cells.
Methods: We used a combination of expression analysis by qRT/PCR and RNA sequencing to determine the
transcriptional activation of FRG2 and DUX4. We examined this in both differentiating control and FSHD derived
muscle cell cultures or DUX4 transduced control cell lines. Next, we used ChIP-seq analysis and luciferase reporter
assays to determine the potential DUX4 transactivation effect on the FRG2 promoter.
Results: We show that DUX4 directly activates the expression of FRG2. Increased expression of FRG2 was observed
following expression of DUX4 in myoblasts and fibroblasts derived from control individuals. Moreover, we identified
DUX4 binding sites at the FRG2 promoter by chromatin immunoprecipitation followed by deep sequencing and
confirmed the direct regulation of DUX4 on the FRG2 promoter by luciferase reporter assays. Activation of luciferase
was dependent on both DUX4 expression and the presence of the DUX4 DNA binding motifs in the FRG2
promoter.
Conclusion: We show that the FSHD-specific upregulation of FRG2 is a direct consequence of the activity of DUX4
protein rather than representing a regional de-repression secondary to fewer D4Z4 repeats.
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Facioscapulohumeral muscular dystrophy (FSHD; OMIM
158900/158901) is one of the most common myopathies
with a prevalence of 1 in 8,000 according to a recent re-
port [1]. Individuals with FSHD typically suffer from pro-
gressive weakening and wasting of the facial and upper
extremity muscles with considerable inter- and intra-
familial variability in disease onset and progression [2].
The pathogenic mechanism of FSHD has been linked to
the polymorphic D4Z4 macrosatellite repeat array, located
on chromosome 4q35, of which each unit contains a copy
of a retrogene encoding for the germline transcription fac-
tor double homeobox protein 4 (DUX4) [3-5]. DUX4 has
been shown to regulate a set of germline, early develop-
ment, and innate immune response related genes and
leads to increased levels of apoptosis when expressed in
muscle cells [6-8]. Over recent years, a combination of de-
tailed genetic and functional analyses in FSHD families
and muscle biopsies has established that sporadic expres-
sion of the DUX4 retrogene in skeletal muscle is a feature
shared by all individuals suffering from FSHD [9,10].
Genetically, at least two forms of FSHD can be recog-
nized. The majority of affected individuals (FSHD1,
>95%) are characterized by a contraction of the D4Z4
repeat array. In healthy individuals, the D4Z4 macrosa-
tellite repeat array consists of 11 to 100 copies, whereas
individuals with FSHD1 have at least one contracted al-
lele of 1 to 10 repeat units [4,5,11]. A second group of
FSHD individuals (FSHD2, <5%) do not show a contrac-
tion of the D4Z4 repeat array, however most often have
mutations in the chromatin modifier structural mainten-
ance of chromosomes hinge domain containing protein
1 (SMCHD1) on chromosome 18p [12]. Both groups
share two important (epi-)genetic features: they carry an
allele permissive for stable DUX4 transcription because
of the presence of a polymorphic DUX4 polyadenylation
signal (PAS) and they display epigenetic derepression of
the D4Z4 repeat array in somatic tissue [9,13]. More
specifically, in muscle biopsies and muscle cell cultures
DUX4 expression has been correlated with decreased
levels of CpG methylation and repressive histone modifi-
cations together with increased levels of transcriptional
permissive chromatin markers at D4Z4 [10,14-17]. The
epigenetic changes at D4Z4 can be either attributed to
repeat array contraction (FSHD1) or loss of SMCHD1
activity at D4Z4 (FSHD2) [2].
The time interval between the genetic association of
FSHD to the D4Z4 macrosatellite repeat array and the
identification of sporadic DUX4 activation as a unifying
disease mechanism encompasses almost 20 years of re-
search into different candidate genes for FSHD [4,9]. In
the absence of a conclusive disease mechanism, genes
proximal to the D4Z4 repeat have been investigated as
possible FSHD disease genes, postulating that theirregulation is affected in FSHD through a position effect
emanating from the D4Z4 repeat array [16-22]. Among
those candidate genes were FSHD Region Gene 1
(FRG1) and FSHD Region Gene 2 (FRG2) (Figure 1A).
FRG1 is located on chromosome 4 at 120 kb proximal to
the D4Z4 repeat and encodes a protein involved in actin
bundle organization and mRNA biogenesis and trans-
port [23-26]. Its overexpression leads to a dystrophic
phenotype in different animal models, probably by af-
fecting actin bundling and splicing of transcripts encod-
ing muscle effector proteins [27-30]. However, most
studies have failed to demonstrate FRG1 upregulation in
FSHD muscle [17,19,20,31-40]. FRG2 is a gene at 37 kb
distance from the repeat encoding a nuclear protein of
unknown function [41]. The distal end of chromosome 4
that contains the D4Z4 macrosatellite repeat array has
been duplicated to chromosome 10 [42,43]. Conse-
quently, due to its close proximity to the D4Z4 repeat
array, FRG2 is located on both chromosomes 4 and 10
(Figure 1A). Additionally, a complete copy of FRG2 has
been identified on the short arm of chromosome 3. We
and others have previously reported on FSHD-specific
transcriptional upregulation of FRG2 from both the 4q
and 10q copies upon in vitro myogenesis, however its
overexpression did not lead to a dystrophic phenotype in
a transgenic mouse model [17,27,31,41].
Until the discovery that mis-expression of DUX4 is
shared by all FSHD individuals, these observations led to a
disease model in which the contraction of the D4Z4 repeat
array would create a position effect on proximal genes,
thereby leading to their transcriptional activation. Such a
mechanism cannot explain the activation of the 10q copy
of FRG2, as this would require a trans-effect of the
contracted repeat array. Although the D4Z4 copies on 4q
and 10q have been shown to interact in interphase nuclei
[44], this seems unlikely as 3D FISH approaches have re-
vealed that the 4q D4Z4 repeat localizes to the nuclear
periphery, whereas the 10q subtelomere does not [45].
More recently, it was shown that the expression of FRG2
in FSHD cells was influenced by telomere length through
telomere position effects [46], leading to the conclusion
that DUX4 and FRG2 were independently regulated by
telomere-length. In the current study we provide evidence
that the activation of FRG2 is a direct consequence of
DUX4 protein activity, providing an experimentally sup-
ported cause for its specific expression in FSHD muscle
and reconfirming DUX4 as the FSHD disease gene.
Methods
Cell culture
Human primary myoblast cell lines were obtained from the
University of Rochester biorepository (http://www.urmc.
rochester.edu/fields-center/) and were expanded and main-
tained in DMEM/F-10 (#31550 Gibco/Life Technologies,
Figure 1 FRG2 activation in FSHD derived differentiating myoblasts. (A) Schematic representation of the FSHD locus on chromosome 4q35.
Rectangles indicate the different genes, arrows their transcriptional direction. Triangles represent D4Z4 repeat units and the single inverted repeat
unit upstream of FRG2. Each unit contains the full DUX4 ORF, only the last repeat unit produces a stable transcript in FSHD patients. The dashed
line indicates the duplicated region present on chromosome 10q26. (B) qRT-PCR analysis of mean FRG2 expression levels in control (C), FSHD1
(F1) and FSHD2 (F2) derived proliferating myoblasts (MB) and differentiating myotubes (MT) shows the significant activation of FRG2 during
differentiation only in F1 and F2 derived cells. Relative expression was determined using GAPDH and GUSB as reference genes. Sample numbers
are indicated and error bars represent the standard error of the mean. Asterisks indicate significant differences based on a one-way ANOVA
(P = 0.0014), followed by pairwise comparison using Bonferroni correction, NS = non-significant. (C) Genomic snapshot (location indicated at the
bottom) of RNA sequencing data of two control, two FSHD1 and two FSHD2 derived proliferating myoblasts (MB) and differentiating myotubes
(MT) confirms the full length expression of FRG2 in differentiating myotubes originating from FSHD individuals.
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inactivated fetal bovine serum (FCS #10270 Gibco), 1%
penicillin/streptomycin (#15140 Gibco), 10 ng/mL rhFGF
(#G5071 Promega, Leiden, The Netherlands) and 1 μM
dexamethasone (#D2915 Sigma-Aldrich, Zwijndrecht, The
Netherlands). Differentiation into myotubes was started at
80% confluency by serum starvation in DMEM/F-12 Glu-
tamax (#31331, Gibco) supplemented with 2% KnockOut
serum replacement formulation (#10828 Gibco) for 36 h.
All samples and their characteristics used for our study
are listed in Additional file 1: Table S1. Rhabdomyosar-
coma TE-671 were maintained in DMEM (#31966) sup-
plemented with 10% FCS and 1% P/S (all Gibco).
RNA isolation, cDNA synthesis, and qRT-PCR
Cells were harvested using Qiazol lysis reagent (#79306
Qiagen N.V., Venlo, The Netherlands) and RNA wassubsequently isolated using the miRNeasy Mini Kit
(#217004 Qiagen) including an on column DNase treat-
ment according to the manufacturer’s instructions. A total
of 2 μg RNA was used to synthesize poly-dT primed
cDNA using the RevertAid H Minus First strand cDNA
Synthesis Kit (#K1632 Thermo Fischer Scientific Inc.,
Waltham, MA, USA). Relative FRG2 expression was
quantified on the CFX96 system (Bio-Rad, Veenendaal,
The Netherlands) using SYBR green master mix (Bio-Rad)
with the following primers: FRG2_Fw: GGGAAAACTG
CAGGAAAA, FRG2_Rv: CTGGACAGTTCCCTGCTGT
GT. For relative quantification GUSB and GAPDH were




TGGAATTTTGCCGATT. All PCR reactions were carried
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Rad CFX manager version 3.0 (Bio-Rad).
Luciferase reporter assays
Genomic fragments containing the FRG2 promoter were
amplified by regular PCR (primers pFRG2 _Fw: AGGC
CTTACCTTGCCTTTGT; pFRG2_Rv: TCTTGCTGGT
GGATGTTGAG) using cosmids 23D11 (chromosome
10) and cY34 (chromosome 4) [47,48]. The obtained PCR
fragments containing the promoter sites were digested
with BglII and BclI and subcloned into the BglII digested
pGL3 basic vector. Genomic locations of the cloned pro-
motersites (UCSC hg19): chr4:190,948,283-190,949,163
and chr10:135,440,170-135,441,050. DUX4 binding sites
were deleted by ligating PCR products obtained with
internal primers (Fw_internal: ATCTGAGGGCCCTGAT
TCCTGAGGTAGC, Rv_internal: ATCTGAGGGCCCCA
TTTTTAAGGTAGGAAGG) combined with RV3 and
GL2 primers annealing in the pGL3 backbone. Single
binding sites were destroyed using site directed mutagen-
esis by PCR amplifying overlapping fragments with the
following primers: Site 1Fw: CCTCAGGAATCAGGGGC
TACATAGGGTAGCACTGACTCAACCT, Site 1Rv: AG
GTTGAGTCAGTGCTACCCTATGTAGCCCCTGATTC








with RV3 and GL2 primers. Insert sequences and correct
orientation in the pGL3 vector were confirmed by Sanger
sequencing. Sixty thousand TE671 cells were seeded in
standard 24 well tissue culture plates and co-transfected
with 200 ng pCS2/pCS2-DUX4 and 200 ng of the indi-
cated pGL3 constructs, using lipofectamine 2000 ac-
cording to manufacturer’s instructions. Twenty-four
hours after transfection cell lysates were harvested and
luciferase activity was measured using the Promega lu-
ciferase assay kit, according to manufacturer’s instruc-
tions. Co-transfection with Renilla luciferase constructs
for data normalization was omitted as we previously ob-
served regulation of this construct by DUX4 [49].
Transfections were carried out in triplicate, error bars
indicate the SEM of three independent experiments.
RNA sequencing and ChIP sequencing
RNA sequencing and ChIP sequencing data were obtained
and analyzed as described before [6,36]. All datasets have
previously been made publicly available in the Gene Expres-
sion Omnibus (accession numbers GSE56787, GSE33838).
FRG2 expression in response to DUX4 overexpression isdisplayed for MB135, a control derived primary myoblast,
and a control derived fibroblast. The genomic snapshots
of the different datasets were generated using the IGV
genome viewer version 2.3.32 [50,51].
Results
FRG2 expression is activated in differentiating FSHD
derived muscle cells
We cultured a set of primary muscle cells derived from
six controls, six FSHD1, and nine FSHD2 individuals
and harvested RNA to analyze FRG2 transcript levels by
quantitative realtime-PCR (qRT-PCR). We confirmed
the significant FSHD-specific activation of FRG2 in dif-
ferentiating myotubes (Figure 1B). In control samples,
we observed a minor increase in FRG2 expression that
was not statistically significant (Figure 1B). Analysis of
previously published RNA-seq data from two additional
controls and a subset of FSHD samples confirmed FRG2
activation (Figure 1C) and single base pair variations,
known to differ between the three copies of FRG2 [41],
indicated transcripts were induced from FRG2 genes at
all three genomic locations (Figure 2). Therefore, we
conclude that increased transcription of FRG2 is not re-
stricted to the copy on the 4q disease allele in FSHD1
and likely not caused by a cis effect of D4Z4 chromatin
relaxation. The increase of FRG2 transcript levels coin-
cided with activation of DUX4 transcription upon in vitro
myogenesis in FSHD derived samples (Additional file 2:
Figure S1), as was reported before by us and others
[36,52,53]. Altogether this confirms previously published
data and highlights the robust transcriptional activation of
all annotated copies of FRG2 in differentiating FSHD
myotubes.
FRG2 activation is a direct consequence of DUX4 protein
activity
As the activation of FRG2 in FSHD-derived myotubes
follows the pattern of previously identified DUX4 target
genes, we wondered if FRG2 is regulated by DUX4 dir-
ectly. Indeed, we previously showed that FRG2 tran-
scription was induced at least two-fold by expression
array analysis in DUX4 over-expressing control myo-
blasts [6]. This robust increase in FRG2 transcription
was confirmed by RNA-seq in both myoblasts and fibro-
blasts (Figure 3A) that were transduced with DUX4 ex-
pressing lentiviruses, ruling out a muscle specific effect
of DUX4 on FRG2 expression. Direct targets of DUX4
were previously identified by overlaying expression data
with chromatin immuno-precipitation (ChIP) sequen-
cing data [6]. Following the same approach, we observed
DUX4 binding at the promoter of FRG2 (Figure 3B).
Sequence analysis of the 4q and 10q copies of the FRG2
promoter revealed that both chromosomes harbor three
consensus binding sites for DUX4, which are not affected
Figure 2 Sequence analysis of RNA sequencing reads reveals activation of FRG2 from all copies. Graphical representation of RNA-seq reads
mapping to the FRG2C locus at chromosome 3p. Single nucleotide polymorphisms can be identified and are indicated by colored vertical lines
(A = green, C = blue, G = orange, T = red). Different reads could thereby be assigned to the three different genomic copies of FRG2. Sequence
analysis was based on the reference sequences obtained from the UCSC genome browser (build 19).
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(Figure 3C). To test the functional significance of these
DUX4 binding sites, we designed luciferase reporter
constructs harboring the FRG2 promoters of chromo-
somes 4 and 10. Co-transfection of these constructs
with pCS2-DUX4 or the empty pCS2 backbone in TE-
671 rhabdomyosarcoma cells confirmed that the activa-
tion of FRG2 is mediated by DUX4 protein expression
(Figure 3D). To confirm that the activation of the lucif-
erase reporter gene was indeed mediated by DUX4
binding, we generated a reporter construct with a
micro-deletion of all three DUX4 binding sites in the
FRG2 promoter derived from chromosome 10 (10Δ,
Figure 3C). Upon co-transfection with the PCS2-DUX4
expression vector, the luciferase activation was com-
pletely ablated (Figure 3D). We identified three con-
secutive DUX4 binding sites in the FRG2 promoter, of
which sites one and three contain a single base pair
variation in the core sequence identified previously [6].
To dissect which sites were responsible for DUX4
dependent FRG2 activation, we designed three add-
itional constructs, in which one of the three sites was
destroyed by site directed mutagenesis (Figure 3C).
Upon transfection of these constructs we observed that
the activation of FRG2 by DUX4 is mediated primarily
through the two binding sites furthest from the FRG2
transcriptional start site (TSS), as luciferase activity in
response to DUX4 expression was no longer signifi-
cantly induced. While destruction of the first binding
site resulted in a complete absence of luciferaseactivation, the effect of DUX4 is still moderate, but
non-significant, if site two is mutated (Figure 3D).
Destroying the third binding site did not affect the DUX4
mediated activation of the FRG2 promoter (Figure 3D).
Altogether, our data show that DUX4 binding at the FRG2
promoter is underlying the transcriptional activation of
FRG2 in FSHD derived myogenic cultures.
Discussion
Ever since the D4Z4 macrosatellite repeat array was gen-
etically associated with FSHD, great effort has been put
into identifying the underlying disease mechanism. The
initial lack of evidence for active transcription of DUX4,
encoded in each D4Z4 repeat unit, shifted the focus to
genes immediately centromeric to the array, like FRG1
and FRG2. Although FRG1 overexpression in mice leads
to a dystrophic phenotype, its deregulation in muscles of
FSHD patients has not been consistently demonstrated
[19,27,28,31-34,36-40]. In contrast, upregulation of FRG2
was consistently reported in FSHD-derived differentiating
muscle cells; however the mechanism of FSHD-specific
upregulation of FRG2 had not been conclusively estab-
lished [17,31,41].
Activation of FRG2 in FSHD cells was previously attrib-
uted to de-repression through a position effect mechanism
secondary to the contraction of the D4Z4 repeat array
[17,41]. Moreover, it was shown that KLF15 regulates both
FRG2 expression and the activity of a putative enhancer in
within D4Z4, thereby possibly facilitating a cis effect of the
D4Z4 repeat array on the proximal FRG2 locus [54]. This
Figure 3 FRG2 is activated as a consequence of DUX4 protein activity at its promoter. (A) Genomic snapshot (location indicated at the
bottom) of mapped RNA-seq reads at the chromosome 4q FRG2 locus. Overexpression of DUX4 results in the activation of FRG2 in myoblasts
and fibroblasts, GFP overexpression was used as a control. (B) Graphical representation of DUX4 binding at the 4q FRG2 promoter (genomic
snapshot location indicated at the bottom) as revealed by ChIP-seq analysis (data obtained in myoblasts). (C) Genomic fragments obtained from
chromosomes 4 and 10 were cloned upstream of the luciferase gene. Polymorphisms distinguishing both copies are indicated (Variants 1-3)
and the three identified DUX4 binding sites are displayed, with nucleotides matching the previously identified core DUX4 binding sequence
underlined. All numbers show the relative distance to the TSS of FRG2, in the 10mut1-3 constructs the number indicates the first displayed nucleotide.
The 10Δ construct lacks all three DUX4 binding sites, whereas in 10mut1-3 the red nucleotides were mutated to the nucleotides indicated below them,
thereby destroying the individual DUX4 binding sites. (D) DUX4 activates the FRG2 promoter in a luciferase reporter assay. Both the 4q and 10q copy
of the FRG2 promoter are activated by DUX4. The 10q copy lacking the DUX4 binding sites (10Δ) was not activated by DUX4. Destruction of the
three individual binding sites revealed that sites 1 and 2 are mediating the DUX4 dependent activation of FRG2. Counts per second (CPS) are a direct
measure of luciferase activity, error bars indicate the SEM of three independent experiments. Asterisks indicate significant differences based on a
one-way ANOVA (P <0.0001), followed by pairwise comparison using Bonferroni correction. NS = non-significant.
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levels at a single CpG site centromeric to D4Z4 are un-
affected in FSHD [13], indicating that DNA methylation
was not broadly altered in the region centromeric to the
D4Z4 repeat array in FSHD cells. The recent establish-
ment of a unifying disease mechanism for FSHD, that pri-
marily centers around DUX4, further challenges a position
effect model that involves the deregulation of genes prox-
imal to D4Z4 as a consequence of D4Z4 repeat array con-
traction. In line with this notion, we now show that FRG2
is a direct target gene of DUX4, providing a direct explan-
ation for its upregulation in FSHD muscle.As sporadic DUX4 activation is induced during
in vitro muscle cell differentiation, the expression profile
of FRG2 fits that of previously reported DUX4 target
genes. It is interesting to note that we observed
increased, though non significant, FRG2 expression in
control derived differentiating muscle cells, which might
indicate a minimal activation of the locus during in vitro
myogenesis in control cells. DUX4 expression has been
reported to occur in control derived myogenic cultures,
albeit at much lower frequencies, and thus FRG2 may be
activated as a consequence of that [55]. Alternatively,
FRG2 expression may be sporadically induced through
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tion by KLF15 [54].
DUX4 acts a potent transcriptional activator and in-
duces expression of germline and early development
genes through binding a specific homeobox sequence
[6]. ChIP-seq analysis indeed identified DUX4 binding at
the promoter of FRG2, which contains three consecutive
DUX4 binding sites. Our experiments showed that the
two sites furthest from the TSS of FRG2 are mediating
the activation of FRG2 upon the expression of DUX4,
confirming our earlier work showing that the probability
of transcriptional activation by DUX4 increases with the
number of consecutive DUX4 binding sites [56]. The
FRG2 promoter sites at chromosomes 3, 4, and 10 are
highly conserved, with identical sequences for the DUX4
sites on 4 and 10 and a limited number of single nucleo-
tide differences between these and chromosome three
that are predicted to preserve DUX4 binding, explaining
the activation of all copies by DUX4 [41]. In contrast to
the complicated proposed mechanism of cis and trans
effects of D4Z4 contraction at 4q [17,41], the protein ac-
tivity of DUX4 offers a simple and experimentally sup-
ported explanation for the activation of FRG2.
It was previously shown that FRG2 and DUX4 are regu-
lated, at least in part, by telomere position effects [46].
Trans-activation of the FRG2 promoter was ruled out by
transfecting promoter reporter constructs in immortalized
FSHD derived myoblasts. However, the sporadic nature of
DUX4 expression in these cells would seriously decrease
the signal-to-noise ratio in this assay and a direct effect of
DUX4 on FRG2 expression would likely have been missed.
Although we cannot rule out a direct telomere position ef-
fect on FRG2 in this study, we suggest that the observed
increase of FRG2 can be attributed to the increased DUX4
levels rather than to telomere position effects on FRG2.
DUX4 itself may indeed be partially under control of telo-
mere length and as such its target genes would follow a
similar regulation.
As of yet, the functional consequence of FRG2 activa-
tion in FSHD remains elusive. FRG2 localizes to the nu-
cleus [41], but its function has never been demonstrated
and a possible role in FSHD disease progression is there-
fore unclear. The identification of FSHD individuals with
proximally extended deletions, in which not only a large
part of the D4Z4 repeat array, but also proximal se-
quences (including FRG2) were deleted, again suggests
that a cis-acting effect on FRG2 is not necessary for
FSHD pathology [57,58]. However, since DUX4 activates
other genomic copies of FRG2, it remains possible that
this protein contributes to some aspect of the disease.
Conclusion
In this study we have firmly established that the long
known activation of FRG2 in FSHD derived differentiatingmuscle cells is a direct consequence of DUX4 activity at
its promoter. This provides further evidence for DUX4 as
the central player in the FSHD disease mechanism and
demonstrates that the higher expression of FRG2 in FSHD
does not result from regional de-repression secondary to
fewer D4Z4 repeats.
Additional files
Additional file 1: Table S1. Characteristics of samples used for qRT-PCR
and RNA-seq analysis. Length in kb and haplotype of both 4q D4Z4
alleles are indicated.
Additional file 2: Figure S1. RNA-sequencing reads mapping to D4Z4
showed DUX4 activation in differentiating FSHD derived muscle cells.
Graphical representation of RNA-seq reads mapping to the 4q D4Z4
repeat, indicative for DUX4 expression, showed FSHD specific activation
of DUX4 upon differentiation. Sequenced transcripts were mapped to
DUX4 ORFs, encoded within each D4Z4 repeat, which are annotated
with gene symbols DUX2, DUX4, DUX4L4, and DUX4L5. MB = myoblasts,
MT = myotubes; the genomic location of the snapshot is indicated at
the bottom.
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